Empirical PPIs Linked to 60% Increase in Asthma Exacerbations

Proton Pump Inhibitors Worsen Biologic-Treated Asthma Outcomes

Adults with asthma who take proton pump inhibitors without an ulcer-related indication face a 60% increase in exacerbations over the next year.

Adults with asthma who take empirical proton pump inhibitors face higher rates of exacerbations and hospital visits, Medscape reported.

Researchers presented these findings on October 20 at the American College of Chest Physicians Annual Meeting in Phoenix. The retrospective study evaluated patients treated with biologics between 2014 and 2025.

Patients taking proton pump inhibitors without an ulcer-related indication experienced a 60% increase in asthma exacerbations over the next year. They also required more rescue systemic corticosteroids and faced a greater risk of respiratory infections.

“Clinicians should carefully reassess the necessity of chronic PPI therapy in biologic-treated asthma patients without clear ulcer-related indications,” Navneet Gupta, MBBS, an internal medicine physician at Allegheny Health Network in Pittsburgh, told attendees.

Clinical Characteristics and Matched Cohort Data

The study analyzed data from the TriNetX US Collaborative Network. Investigators tracked adults aged 18 and older receiving biologics such as omalizumab, mepolizumab, benralizumab, reslizumab, dupilumab, or tezepelumab.

Before matching, patients taking acid suppressors were roughly 10 years older. They also showed higher rates of baseline conditions like hypertension and diabetes.

Clinical Outcome PPI Users Nonusers
Asthma Exacerbations 31.9% 22.6%
Systemic Corticosteroid Use 72% 40%
Respiratory Infections 8.4% 2.3%
Emergency Room Visits 15.6% 8.4%
ICU Admissions 4.3% 1.2%

Gupta suggested proactive medication reconciliation and structured deprescribing strategies to reduce unnecessary long-term exposure. Patients often continue the medication after resolving short-term symptoms.

Real-World Evidence on Inappropriate Acid Suppressor Use

Many patients retain the regimen long after an initial short-term indication resolves.

“I think it was important for a real-world study to be done with PPI because a lot of these trials that had been done over 10 years ago, and yet still I see clinicians using PPI inappropriately in uncontrolled asthma,” Mario Castro, MD, MPH, a professor of medicine and chief of the Division of Pulmonary, Critical Care and Sleep Medicine at the University of Kansas Medical Center in Kansas City, told attendees.

Castro was not involved in the research. He emphasized that the findings supply solid evidence for avoiding inappropriate administration when clear clinical indicators are absent.

Asthma Medication Safety Questions

Why do patients with asthma receive proton pump inhibitors?

Clinicians sometimes prescribe these medications for short-term gastrointestinal symptoms, but patients often continue taking them indefinitely without a documented ulcer-related indication.

What specific risks did the Phoenix study identify?

The analysis linked empirical use to higher rates of asthma exacerbations, respiratory infections, emergency room visits, and intensive care unit admissions.

Were there any differences in patient mortality?

The study found no significant differences in all-cause mortality between patients taking proton pump inhibitors and those not taking them.

“If you have a clear clinical indication for a PPI, yes. But if you don’t, don’t do it for uncontrolled asthma,” Castro told attendees.